Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation

Phase 4 Completed 38 enrolled University of Miami Hoffmann-La Roche · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

To observe in a randomized prospective pilot study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor (LD) kidneys, compared with our standard treatment protocol of Zenapax® and maintenance immunosuppression

Timeline

Start: 2002-09
Primary completion: 2006-10
Completion: 2007-10

Publications

Ciancio G, Gaynor JJ, Guerra G, Sageshima J, Chen L, Mattiazzi A, Roth D, Kupin W, Tueros L, Flores S, Hanson L, Vianna R, Burke GW 3rd. Randomized trial of three induction antibodies in kidney transplantation: long-term results. Transplantation. 2014 Jun 15;97(11):1128-38. doi: 10.1097/01.TP.0000441089.39840.66.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alemtuzumab	Monoclonal antibody	—	—
Subject	Daclizumab	Monoclonal antibody	—	—
Subject	Thymoglobulin	Protein / enzyme biologic	—	—

Indications

No indication recorded.